Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Research & Development (2022 - 2026)

Sagimet Biosciences' Research & Development history spans 5 years, with the latest figure at $7.0 million for Q1 2026.

  • Quarterly Research & Development fell 54.41% to $7.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $30.7 million through Mar 2026, down 36.72% year-over-year, with the annual reading at $39.1 million for FY2025, 1.59% up from the prior year.
  • Research & Development came in at $7.0 million for Q1 2026, up from $6.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $15.3 million in Q1 2025 to a low of $4.5 million in Q1 2023.
  • The 5-year median for Research & Development is $6.6 million (2022), against an average of $7.7 million.
  • Year-over-year, Research & Development surged 191.56% in 2025 and then tumbled 54.41% in 2026.
  • Sagimet Biosciences' Research & Development stood at $5.8 million in 2022, then fell by 3.27% to $5.7 million in 2023, then surged by 151.34% to $14.2 million in 2024, then crashed by 52.63% to $6.7 million in 2025, then grew by 3.88% to $7.0 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Research & Development are $7.0 million (Q1 2026), $6.7 million (Q4 2025), and $9.7 million (Q3 2025).